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SYNOPSIS
We describe laboratory-conﬁ  rmed inﬂ  uenza A pandem-
ic (H1N1) 2009 in 17 hospitalized recipients of a hematopoi-
etic stem cell transplant (HSCT) (8 allogeneic) and in 15 
patients with malignancy treated at 6 Australian tertiary cen-
ters during winter 2009. Ten (31.3%) patients were admit-
ted to intensive care, and 9 of them were HSCT recipients. 
All recipients of allogeneic HSCT with infection <100 days 
posttransplantation or severe graft-versus-host disease 
were admitted to an intensive care unit. In-hospital mortality 
rate was 21.9% (7/32). The H275Y neuraminidase muta-
tion, which confers oseltamivir resistance developed in 4 of 
7 patients with PCR positive for inﬂ  uenza after >4 days of 
oseltamivir therapy. Three of these 4 patients were critically 
ill. Oseltamivir resistance in 4 (13.3%) of 30 patients who 
were administered oseltamivir highlights the need for ongo-
ing surveillance of such resistance and further research on 
optimal antiviral therapy in the immunocompromised.
I
mmunocompromised patients are at risk for serious 
complications from seasonal inﬂ  uenza (1). This group 
of patients has also been disproportionately represented 
among those with severe infections from inﬂ  uenza A pan-
demic (H1N1) 2009, comprising 3.4%–19.6% of patients 
admitted to intensive care units in case series from North 
America (2–4).
The protective effect of seasonal inﬂ  uenza vaccination 
is reduced in patients with hematologic malignancy and 
recipients of an allogeneic hematopoietic stem cell trans-
plant (HSCT) (5,6). Therefore, these patients are likely to 
remain at increased risk for complications from the pan-
demic (H1N1) 2009 virus, despite the availability of an ef-
fective vaccine. Furthermore, the emergence of resistance 
to neuraminidase inhibitors may limit the utility of prophy-
laxis in this population (7–12).
During 2009, the predominant strain of inﬂ  uenza in 
Australia was inﬂ  uenza A pandemic (H1N1) 2009 virus 
(13,14). In the state of Victoria, after the initial 3 months of 
community transmission of pandemic (H1N1) 2009 virus, 
50% of patients who died had an underlying hematologic 
malignancy (15). We describe in detail the clinical features, 
treatment, and outcomes of immunocompromised patients 
hospitalized in 6 tertiary centers in Australia during winter 
2009.
Study Design and Population
Six Australian tertiary centers, 5 in Melbourne, Victo-
ria, and 1 in Sydney, New South Wales (NSW), participat-
ed in the study. The 5 centers in Melbourne provide most 
specialist adult hematology services to the state of Victoria 
(population 5.4 million), and 2 of these centers perform all 
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allogeneic HSCTs for the state. The participating Sydney 
center is the largest of 2 centers that perform adult alloge-
neic HSCT for the state of NSW (population 7 million). 
Approval for this study was obtained from human research 
ethics committees of each center.
Patients were included in the study if they had the fol-
lowing characteristics: 1) >18 years of age hospitalized at 
1 of the 5 Melbourne study centers during May 1–August 
30, 2009, or hospitalized at the Sydney center during May 
1–September 15, 2009; 2) recipient of an HSCT or had an 
underlying malignancy (hematologic or solid tumor); and 
3) had laboratory-conﬁ  rmed pandemic (H1N1) 2009 virus 
infection identiﬁ  ed by nucleic acid testing (NAT) during 
their hospital stay. At each center, investigators were di-
rectly involved in active surveillance and management of 
patients with pandemic (H1N1) 2009, allowing cases to be 
identiﬁ  ed. Data were retrospectively abstracted onto stan-
dardized case record forms.
Inﬂ  uenza Virus Diagnostics
All cases were conﬁ  rmed in laboratories whose perfor-
mance is accredited by the National Association of Test-
ing Authorities in Australia. For the Victorian cases, all 
but 1 case-patient had laboratory conﬁ  rmation of pandemic 
(H1N1) 2009 at the Victorian Infectious Diseases Reference 
Laboratory (VIDRL) with pandemic (H1N1) 2009–speciﬁ  c 
NAT by using reverse transcriptase–PCR (RT-PCR) as de-
scribed (16). NAT for the other case-patient from Victoria 
was performed by the laboratory at the hospital where the 
patient was treated. The NSW cases were all conﬁ  rmed at 
the state’s reference laboratory with RT-PCR assays as pre-
viously described (17). Patient specimens had repeat NAT 
at the discretion of the treating clinicians. Virus isolates 
or clinical samples from patients whose NAT results were 
positive after 4 days of oseltamivir therapy were analyzed to 
determine the presence of the H275Y neuraminidase (NA) 
mutation (N1 numbering) by using either a pyrosequenc-
ing assay (Biotage AB, Uppsala, Sweden) according to the 
manufacturer’s instructions, or rolling circle ampliﬁ  cation 
(18). The H275Y mutation confers high-level oseltamivir 
resistance and has been detected in all of the oseltamivir-
resistant pandemic (H1N1) 2009 viruses reported to date, 
as well as in local circulating seasonal inﬂ  uenza A (H1N1) 
strains (8,12). Samples also underwent NAT for other re-
spiratory viruses by using a multiplex PCR.
Deﬁ  nitions and Statistics
Data were stored in Microsoft Access 2003 (Micro-
soft, Redmond, WA, USA), and descriptive statistics were 
summarized with proportional outcomes. Nosocomial ac-
quisition was deﬁ  ned as the development of symptoms at-
tributable to pandemic inﬂ  uenza after 48 hours in the hos-
pital that were not present on admission. Steroid-refractory 
or grade III–IV graft-versus-host-disease (GVHD) was de-
ﬁ  ned as severe GVHD.
Length of stay was calculated as length of hospital ad-
mission or period of conﬁ  nement after onset of symptoms 
for those with nosocomial acquisition. Epidemic curves for 
the 2 states were aligned with epidemic curves of commu-
nity pandemic inﬂ  uenza activity ascertained from surveil-
lance data (14,19). Daily corticosteroid doses were calcu-
lated by using relative glucocorticoid potency to convert 
to prednisolone equivalents, and mean daily values were 
determined for patients who received regular intermittent 
dosing (20).
Thirty-two patients fulﬁ  lled the inclusion criteria. Pa-
tient demographics and clinical features are summarized 
in Table 1. Seven (21.7%) of the 32 patients died; median 
length of stay was 6.5 d (interquartile range 4.0–13.5 d).
Patient Demographics and Baseline Features
Eight patients were recipients of an allogeneic HSCT 
(Table 1). Six patients had a human leukocyte antigen 
(HLA) matched related, 1 (patient 1) an HLA mismatched 
related, and 1 (patient 7) an HLA matched unrelated al-
logeneic HSCT. Patient 6 was the recipient of 2 allogeneic 
HSCTs. Three patients (5, 6, and 8) were diagnosed with 
pandemic (H1N1) 2009 within 100 days of the allogeneic 
HSCT. Six were receiving calcineurin inhibitors. Patient 
3 was the only allogeneic HSCT recipient that had docu-
mented recurrence of underlying disease posttransplant.
At the time they sought treatment, all 8 recipients of 
autologous HSCT were >2 years posttransplant. These pa-
tients had their malignancy diagnosed between 5 and 8 years 
before pandemic (H1N1) 2009, except patient 11, who had 
multiple myeloma that had been diagnosed 3 years previ-
ously. All autologous HSCT recipients had a relapse of ma-
lignancy after transplantation, and 7 of these patients were 
continuing to receive active treatment for malignancy.
Two patients (26 and 29) who had had recent a diag-
nosis of malignancy were in remission and continuing on 
the primary chemotherapy treatment plan. Seven nontrans-
plant recipients had either not shown a response or were 
deemed by their treating clinicians to be refractory to their 
current treatments. Patient 17 had an inﬂ  uenza-like illness 
(ILI) before admission for chemotherapy and autologous 
HSCT (further details below). Sixteen patients (3 alloge-
neic HSCT recipients, 6 autologous HSCT recipients, and 
10 nontransplant recipients) were receiving corticosteroids 
before the onset of pandemic (H1N1) 2009 infection. The 
mean dose in prednisolone equivalents was 40.9 mg/d 
(range 5.0–156 mg/d).
Findings at Initial Visit
Clinical features at patients’ initial visit coincided with 
peak activity of pandemic (H1N1) 2009 in the Victorian and 
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NSW communities (Figure; online Technical Appendix, 
www.cdc.gov/EID/content/16/7/1068-Techapp.pdf). Pa-
tient 17 acquired the infection during interstate travel and 
sought treatment in late August, 2 days after return to Mel-
bourne. Four patients had contact with family members 
with ILI, and 4 patients had nosocomial acquisition without 
an identiﬁ  able primary or index case (Table 1).
Most patients exhibited fever (94%) and cough (91%). 
Dyspnea, sore throat, and rhinorrhea were reported in 53%, 
50%, and 50% of patients, respectively. Sixteen patients 
(50%) sought treatment within 48 h of symptom onset. 
Four patients visited the hospital after experiencing pro-
longed symptoms: for 12 d (patient 4), 14 d (patients 22 
and 25), and 21 d (patient 14). Three of these patients had 
biphasic illnesses with initial prolonged mild upper respira-
tory tract illnesses and, on examination, had consolidation 
shown on chest radiograph. Patient 25 had 2 weeks of dys-
pnea associated with an exacerbation of chronic obstructive 
pulmonary disease. Patient 16 sought treatment for shock 
and respiratory failure.
Diagnosis of pandemic (H1N1) 2009 was conﬁ  rmed 
by NAT of bronchial washings of 3 patients (2, 16, 17). 
One of them, patient 17, had symptoms of a viral respira-
tory tract infection for 20 d with negative results for pan-
demic (H1N1) 2009 virus by RT-PCR of nasopharyngeal 
swab specimens taken 2 and 16 d before bronchoscopy. All 
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Table 1. Demographics and clinical findings among patients who had malignancy or HSCT and influenza A pandemic (H1N1) 2009 
virus, Australia* 
Patient
no. Age, y/sex  Underlying malignancy  Coexisting conditions Acquisition 
Radiographic
infiltrates  ICU Death 
Allogeneic stem cell transplant recipients 
1 44/F Prolymphocytic  leukemia GVHD, renal  Community†  None Yes  Yes 
2 53/F Non-Hodgkin  lymphoma  GVHD‡  Nosocomial Multifocal Yes  Yes 
3 33/M Hodgkin lymphoma None  Community  None  No No
4 57/F CML GVHD§  Community  Unifocal No No
5 61/M Myelodysplastic syndrome  None  Nosocomial Multifocal Yes  Yes 
6 56/M Myelofibrosis GVHD‡  Community  Multifocal Yes  Yes 
7 61/M AML GVHD,§ cardiac Community None  No No
8 63/F AML None  Nosocomial Unifocal Yes  No
Autologous stem cell transplant recipients 
9 70/M Multiple myeloma Pulmonary  Community†  Unifocal Yes  No
10 50/F Multiple myeloma  None  Community  Multifocal Yes  Yes 
11 72/M Multiple myeloma  Type 2 diabetes  Community  None  No No
12 42/F  Multiple myeloma  Type 2 diabetes  Community  Multifocal Yes  No
13 57/M Multiple myeloma None  Community†  Multifocal No No
14 30/F Hodgkins lymphoma  None  Community  Multifocal No No
15 52/F Non-Hodgkins  lymphoma  None  Community None  No No
16 68/M Multiple myeloma Renal Community  Multifocal Yes  Yes 
Patients with no prior stem cell transplant 
17 24/F Hodgkins lymphoma  None  Community¶  None  No No
18 72/M AML Type 2 diabetes  Community  Multifocal No No
19 63/F Multiple myeloma  None  Community  Multifocal No No
20 80/F Aplastic anemia  Cardiac Community  None  No No
21 70/F Hodgkins lymphoma  None  Community  None  No No
22 61/F CLL  None  Community†  Multifocal No No
23 63/F Non-Hodgkin  lymphoma  Pulmonary  Community†  None No No
24 68/M CLL Pulmonary  Community  None  Yes  Yes 
25 76/M CLL Pulmonary  Community  Multifocal No No
26 59/F AML None  Community  None  No No
27 47/F CLL  None  Community  No imaging No No
28 57/M Multiple myeloma None  Community  Unifocal No No
29 56/M Hodgkin lymphoma  Type 2 diabetes  Community  Multifocal No No
30 26/M ALL None Nosocomial No imaging No No
31 55/F Cervical cancer None Community  None  No No
32 50/F Breast cancer  None Community  Multifocal No No
*HSCT, hematopoietic stem cell transplant; ICU, intensive care unit; GVHD, graft-versus-host disease; CML, chronic myeloid leukemia; AML, acute 
myeloid leukemia; CLL, chronic lymphocytic leukemia; ALL, acute lymphocytic leukemia. 
†Household contacts with influenza-like illness identified. 
‡Severe GVHD. 
§Chronic GVHD. 
¶Patient 17 had onset of influenza-like symptoms on returning to Victoria from interstate travel. Oseltamivir Resistance and Pandemic (H1N1) 2009
other patients had the diagnosis conﬁ  rmed on NAT of na-
sopharyngeal swab samples. Six patients (19%) had a base-
line peripheral blood lymphocyte count <200 cells/mL, and 
18 (56%) patients had pneumonia shown on baseline chest 
radiograph.
Antiviral Therapy
Thirty patients (94%) were administered oseltamivir 
therapy. Of these patients, 13 (41%) were administered 
therapy within 48 hours, and 16 began therapy >48 hours 
after symptom onset. Duration of illness before receiving 
oseltamivir was unknown for patient 2. Nine patients re-
ceived NA inhibitors for >5 days. Three of these patients 
(1, 12, 18) had a positive NAT result >5 days after oselta-
mivir treatment began. Antimicrobial drug treatment was 
changed to zanamir for patients 1 and 8 after they received 
initial therapy with oseltamivir (see below). The longest 
duration of antiviral therapy was 43 d (patient 1). Patients 
15 and 31 had uncomplicated infections and were not ad-
ministered oseltamivir therapy.
Co-pathogens
Four patients had notable co-pathogens identiﬁ  ed. Pa-
tient 2 had 4 concurrent herpesviridae (cytomegalovirus, 
Epstein-Barr virus, herpes simplex virus 2, and human her-
pesvirus 6) detected by NAT in respiratory specimens and 
blood. Treatment for patient 2 included liposomal ampho-
tericin B and foscarnet. Patient 7 had Staphylococcus au-
reus bacteremia from an unrelated source. Patient 17, who 
came to transplant with an ILI, had bronchial washings that 
were positive for pandemic (H1N1) 2009 by NAT, galac-
tomannan antigen, and Aspergillus spp. by NAT 5 days af-
ter transplant. Pulmonary nodules consistent with invasive 
fungal infection were seen on a high-resolution computed 
tomography scan. Patient 13 was infected with respiratory 
syncytial virus, which was detected by multiplex NAT on a 
nasopharyngeal swab.
Patients Admitted to Intensive Care Unit
Ten (31.3%) patients were admitted to intensive care 
(Table 1). In each case, the primary reason for admission to 
intensive care was respiratory failure. Seven (70%) of these 
patients died, 6 in intensive care and 1 (patient 5) of recur-
rent pneumonia after being discharged from intensive care. 
Preterminal events included progressive respiratory failure 
(n = 5) and multiorgan failure (n = 2).
All allogeneic HSCT recipients with the following fea-
tures required admission to intensive care for mechanical 
ventilation: transplantation within 100 d, severe GVHD, 
and nosocomial acquisition of pandemic (H1N1) 2009. 
However, onset of symptoms for patient 1 was day 119 af-
ter allogeneic transplantation.
Eight of 10 patients admitted to intensive care had evi-
dence of pneumonia on baseline chest radiograph. Patient 
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Figure. Date of admission to hospitals in Victoria (A) and New South Wales (B), Australia, for patients with underlying malignancy who 
were infected with pandemic (H1N1) 2009, April–October 2009. Twelve Victorian and 4 New South Wales patients were recipients of 
a hematopoietic stem cell transplant. Rates of laboratory detection of all inﬂ  uenza viruses, obtained from population-based epidemic 
surveillance for Victoria and New South Wales, are given in the online Technical Appendix (www.cdc.gov/EID/content/16/7/1068-Techapp.
pdf). SYNOPSIS
1 initially had normal chest radiograph results, despite the 
acute onset of hypoxia. Patient 24 was transferred to inten-
sive care after 3 days in the hospital, at which point bilater-
al inﬁ  ltrates were seen on chest radiograph, and oseltamivir 
therapy was begun.
Oseltamivir Resistance
Ten patients had repeat NAT testing to determine clear-
ance of viral shedding. Eight had >1 further positive NAT (2 
on sputum, 5 on nasopharyngeal swab specimen, and 1 on 
bronchoalveolar lavage sample) after receiving oseltamivir. 
Five of these patients had a positive NAT after >5 d of osel-
tamivir therapy. The longest recorded duration of viral shed-
ding during oseltamivir therapy was 28 d (patient 1).
The H275Y NA mutation, a substitution known to 
confer a high level of oseltamivir resistance, was detected 
in 4 (57%) of 7 patients who had detectable nucleic acid af-
ter >4 d of oseltamivir therapy. These 4 patients comprised 
13.3% of the 30 patients who received oseltamivir. The 
ﬁ  ndings for the 4 patients who were infected with oselta-
mivir-resistant inﬂ  uenza virus are summarized in Table 2. 
The H275Y mutation was undetectable in initial diagnos-
tic samples from these patients. Additionally, the H275Y 
mutation was detected in all available samples collected 
from these patients after they received oseltamivir therapy. 
Three of the 4 patients who had oseltamivir-resistant pan-
demic (H1N1) 2009 virus infection were HSCT recipients 
who had been admitted to intensive care. Virus isolation in 
MDCK cells was attempted for the samples that contained 
the H275Y mutation but was unsuccessful after 2 passages. 
This precluded the use of the phenotypic NA inhibition as-
say to further analyze the samples.
Patient 12, who survived despite shedding oseltami-
vir-resistant pandemic (H1N1) 2009 virus, had a bipha-
sic clinical course. She initially stabilized while she was 
treated with oseltamivir; progressive respiratory failure 
then developed, which coincided with her recovery from 
neutropenia before later improvement. The other patient 
who survived despite shedding oseltamivir-resistant 2009 
pandemic (H1N1) virus (patient 20) had an ILI without 
pneumonia. Of the 2 patients with resistant isolates who 
died, patient 5 ﬁ  rst experienced the apparent resolution of 
pneumonia but later succumbed to recurrent pneumonia, 
and patient 1 had persisting pneumonitis despite 36 days of 
oseltamivir therapy.
Patient 24 had multiple positive NATs, none with the 
H275Y mutant detected. His NAT was positive 4 d after 
he began oseltamivir therapy, and he died 1 d after his last 
specimen, a nasopharyngeal swab, was collected.
Conclusions
We report a case series of hospitalized cancer patients 
with inﬂ  uenza A pandemic (H1N1) 2009 virus infection 
and their outcomes. Patients with hematologic malignan-
cies accounted for 50% of deaths of persons with pandemic 
inﬂ  uenza in Victoria during the ﬁ  rst 3 months of the pan-
demic (15). The strongest effects of illness from pandemic 
inﬂ  uenza among hospitalized cancer patients in the present 
series occurred in HSCT recipients. Nine of the 10 cancer 
patients admitted to intensive care were HSCT recipients. 
Furthermore, of 7 deaths from pandemic (H1N1) 2009 in 
this series of hospitalized cancer patients, 6 occurred in 
HSCT recipients (comprising 37.5% of these patients). Our 
observations are similar to those seen with seasonal inﬂ  u-
enza. In a series of hematology patients with respiratory 
virus infection, including seasonal inﬂ  uenza, from 1 large 
cancer center, the largest number of infections and deaths 
occurred in recipients of allogeneic HSCTs (21). Our ob-
servations support the importance of existing recommen-
dations for control of transmission of inﬂ  uenza infection in 
HSCT recipients during an inﬂ  uenza pandemic (22).
Half of the 24 cancer patients who had not received an 
allogeneic HSCT had underlying multiple myeloma (n = 8) 
and chronic lymphocytic leukemia (n = 4). There was also 
a paucity of patients with solid tumors (n = 2). The severity 
of illness from inﬂ  uenza in patients who have underlying 
multiple myeloma and chronic lymphocytic leukemia has 
not previously been widely appreciated, although a high 
rate of pneumonic illness from inﬂ  uenza has previously 
been demonstrated at 1 center (21). Patients with multiple 
myeloma have impaired cell-mediated immunity, in addi-
tion to humoral immune deﬁ  cits (6,23,24). All 4 patients 
with multiple myeloma admitted to intensive care had pre-
viously received an autologous HSCT, which likely further 
compromised immunologic function. They also had been 
diagnosed with myeloma for several years.
Bacterial co-pathogens that cause pneumonia were not 
identiﬁ  ed in our study cohort. However, patients received 
broad-spectrum antibacterial agents on admission. In con-
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Table 2. Characteristics of 4 patients infected with oseltamivir-
resistant pandemic influenza A (H1N1) virus isolates, Australia*† 
Characteristic
Patient no. 
15 1 2 2 0
Within 100 days of HSCT‡  No Yes  No –
Time to development of 
resistance, d 
22 11§ 8 4
Time of last positive NAT 
result, d 
28 16 8 4
Change to zanamivir  Yes  No No No
Time to zanamivir, d  36 – – –
Died Yes Yes  No No
LOS, d  39 66 21 9
*HSCT, hematopoietic stem cell transplant; NAT, nucleic acid test; LOS, 
length of stay. 
 †Oseltamivir resistance was influenza virus with H275Y mutation. 
‡Time from commencement of oseltamivir. 
§Detected in bronchoalveolar lavage specimen with negative NAT on 
nasopharyngeal swab 3 d before first and 10 d after last bronchoscopy. 
This patient received oseltamivir for 5 d. Oseltamivir Resistance and Pandemic (H1N1) 2009
trast, a small number of investigators have identiﬁ  ed bacte-
rial superinfections in up to 30% of fatal cases of pandemic 
inﬂ  uenza (3,25). For patient 17 in this series, a diagnosis of 
pulmonary aspergillosis was made after autologous HSCT, 
an association previously reported with seasonal inﬂ  uenza 
in allogeneic HSCT recipients (26).
When there is a circulating strain of inﬂ  uenza not con-
tained in the recent inﬂ  uenza vaccine, postexposure oselta-
mivir prophylaxis is an attractive strategy that can prevent 
the development of inﬂ  uenza infection (27–29). Postexpo-
sure prophylaxis of healthcare workers and family members 
may reduce the likelihood of exposure through prevention 
of inﬂ  uenza infection in close contacts of HSCT recipients. 
Our observations that would support post-exposure osel-
tamivir prophylaxis are 1) 4 of 5 allogeneic HSCT recipi-
ents who died or were admitted to intensive care had either 
nosocomial or household acquisition; 2) 5 of 11 HSCT 
recipients who had pneumonia before beginning oseltami-
vir therapy died; 3) none of the patients in this study were 
known to have received postexposure prophylaxis at the 
time of symptom onset, despite use of this strategy during 
the study period (29); and 4) 3 patients acquired the infec-
tion in the hospital from unidentiﬁ  ed sources. This nosoco-
mial transmission occurred despite heightened awareness 
during this pandemic, which demonstrates the difﬁ  culties 
of effective containment in the hospital setting (28,29).
The ﬁ  nding of oseltamivir-resistant inﬂ  uenza virus in 
4 of 7 patients with a positive pandemic (H1N1) 2009–spe-
ciﬁ  c RT-PCR result after >4 d of oseltamivir therapy is a 
cause for concern. In Australia, oseltamivir-resistant pan-
demic (H1N1) 2009 has been described in another immu-
nocompromised patient, a renal transplant recipient (30). 
No oseltamivir-resistant pandemic (H1N1) 2009 strains 
have been detected in nonhospitalized patients in Australia 
(B. Wang and A. Hurt, pers. comm.). The risk of pandem-
ic inﬂ  uenza developing the H275Y mutation that confers 
oseltamivir resistance is considered to be higher in immu-
nocompromised patients (10,12). Immunocompromised 
patients have also been overrepresented in deaths associ-
ated with oseltamivir-resistant seasonal inﬂ  uenza (31,32). 
If repeat NAT on respiratory specimens had been routinely 
performed for all treated patients in the present series, rates 
of oseltamivir resistance may have been even higher than 
we observed. Our ﬁ  ndings indicate an urgent need to opti-
mize oseltamivir dosing in immunocompromised patients. 
Further research into the role of combination antiviral ther-
apy should be considered (33,34). Immunocompromised 
patients should have serial screening for ongoing viral 
shedding and oseltamivir resistance. The oseltamivir-resis-
tant H275Y mutants remain susceptible to the alternative 
NA inhibitor zanamivir, and therefore the use of this drug 
should be considered in patients who are shedding these 
viruses (10).
Only 1 of the patients who was in intensive care and 
had oseltamivir-resistant pandemic (H1N1) 2009 virus sur-
vived. The effects of oseltamivir-resistant inﬂ  uenza virus 
in this patient are uncertain. The deterioration of her con-
dition after initial stabilization may have been related to 
development of oseltamivir-resistance and persistent inﬂ  u-
enza viral replication similar to that seen in a recent case 
report (30). Others have shown development of resistance 
to oseltamivir within 3 d of therapy (30), and we observed 
resistance develop within 4 d for 1 patient. Undoubtedly, 
other explanations for her biphasic illness are possible. Im-
mune recovery with resolution of neutropenia may have 
enabled viral clearance and recovery.
Universal chemoprophylaxis for HSCT recipients 
during an outbreak with an inﬂ  uenza strain that is not con-
tained in the available inﬂ  uenza vaccine has been recom-
mended by international guidelines supported by North 
American and European Blood and Marrow Transplant 
groups, Infectious Diseases Society of America, and the 
US Centers for Disease Control and Prevention (22). One 
of the study centers instituted universal chemoprophy-
laxis for patients admitted to receive an allogeneic HSCT 
after 2 cases of nosocomial-acquired infection before 
engraftment (P. Ferguson, pers. comm.). Although the 
strategy led to apparent success, with no further nosoco-
mial infections observed, we have concern about this ap-
proach based on 1) the high rate of oseltamivir resistance 
(4/30 [13.3%] administered oseltamivir) observed in this 
study; 2) overrepresentation of postexposure prophylaxis 
in cases of oseltamivir-resistant pandemic (H1N1) 2009 
inﬂ  uenza  (12); 3) the potential that pandemic (H1N1) 
2009 H275Y mutant viruses may transmit and spread 
throughout the community, similar to outcomes recently 
observed with seasonal inﬂ  uenza A (H1N1) viruses with 
the same H275Y mutation (8,11,35); and 4) the paucity of 
hospital-acquired cases seen in this series during height-
ened surveillance and control measures of a pandemic. A 
more judicious approach may be surveillance, infection 
control measures, and early treatment until vaccination 
becomes available (12,22,28). Additionally, education of 
patients and their close contacts to facilitate early treat-
ment and avoidance of exposure is essential. When a vac-
cine becomes available, close contacts of those infected, 
their family members, and healthcare workers should be 
vaccinated.
One of the strengths of this study is the relatively high 
coverage of the major hematology centers in a single state, 
which reduces the effect of bias on patient ascertainment. 
However, patients whose treatment was managed in the 
community were excluded, and this information will be es-
sential to our understanding as to which co-factors predict 
clinical progression and outcomes for pandemic (H1N1) 
2009 infection in immunocompromised patients.
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A high rate of oseltamivir resistance developed in criti-
cally ill HSCT recipients, particularly in those who contin-
ued to shed pandemic (H1N1) 2009 virus after 4 d of os-
eltamivir treatment. Consequently, surveillance, infection 
control measures, and early treatment of those at greatest 
risk of pandemic (H1N1) 2009 infection may prove more 
useful than universal chemoprophylaxis during an outbreak 
with an inﬂ  uenza strain that is not contained in the available 
inﬂ  uenza vaccine. Continued surveillance for oseltamivir-
resistant inﬂ  uenza virus strains is needed, particularly in 
the immunocompromised.
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